Credit: Unsplash / CC0 Public Domain

British pharmaceutical company AstraZeneca said Monday that its diabetes drug Farxiga was unsuccessful in treating COVID patients at risk of serious complications, following a study.

AstraZeneca, whose separate rollout of COVID vaccines has been hampered by health concerns, said in its study, “evaluating Farxiga’s potential to treat patients hospitalized with COVID-19 who are at risk of serious complications. .. has not reached statistical significance “.

The study was conducted in conjunction with Saint Luke’s Mid America Heart Institute and looked at possible complications such as diabetes and heart failure.

“Although the study did not reach statistical significance, the results are very interesting and valuable and will influence future clinical science,” Saint Luke cardiologist Mikhail Kosiborod said in a joint statement.

Public confidence in AstraZeneca’s COVID-19 vaccine has now been severely shaken by reports linking it to rare but potentially fatal blood clots and conflicting recommendations about its use.

Follow the latest news on the Coronavirus (COVID-19) outbreak

© 2021 AFP

Quote: AstraZeneca is experiencing a diabetes setback for COVID (2021, April 12), accessed on April 12, 2021 from has been

This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.